Evaluation of the Synergistic Activity of Anidulafungin with Isavuconazole, Voriconazole, Posaconazole, and Amphotericin B in Candida auris (Candidozyma auris) Isolates - PubMed
4 hours ago
- #combination therapy
- #Candida auris
- #antifungal resistance
- Candida auris is a multidrug-resistant fungus posing a global public health threat.
- The study evaluated synergistic activity of anidulafungin combined with isavuconazole, voriconazole, posaconazole, and amphotericin B against C. auris.
- High resistance rates were observed for fluconazole (72%) and amphotericin B (48%), but no resistance to echinocandins.
- Combination tests showed predominantly indifferent interactions (56-84%), with some partial synergy (12-40%).
- A single instance of true synergy was noted with anidulafungin-posaconazole combination in one isolate.
- Anidulafungin-azole combinations showed higher synergy rates (36-40%) compared to anidulafungin-amphotericin B (12%).
- No antagonism was detected in any combination.
- The study suggests combination therapy may not consistently offer strong synergistic benefits for C. auris isolates.